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Abstract
Objective To compare the clinical effectiveness of collaborative care
with usual care in the management of patients with moderate to severe
depression.
Design Cluster randomised controlled trial.
Setting 51 primary care practices in three primary care districts in the
United Kingdom.
Participants 581 adults aged 18 years and older who met ICD-10
(international classification of diseases, 10th revision) criteria for a
depressive episode on the revised Clinical Interview Schedule. We
excluded acutely suicidal patients and those with psychosis, or with type
I or type II bipolar disorder; patients whose low mood was associated
with bereavement or whose primary presenting problem was alcohol or
drug abuse; and patients receiving psychological treatment for their
depression by specialist mental health services. We identified potentially
eligible participants by searching computerised case records in general
practices for patients with depression.
Interventions Collaborative care, including depression education, drug
management, behavioural activation, relapse prevention, and primary
care liaison, was delivered by caremanagers. Collaborative care involved
six to 12 contacts with participants over 14 weeks, supervised by mental
health specialists. Usual care was family doctors’ standard clinical
practice.
Main outcome measures Depression symptoms (patient health
questionnaire 9; PHQ-9), anxiety (generalised anxiety disorder 7; GAD-7),
and quality of life (short form 36 questionnaire; SF-36) at four and 12
months; satisfaction with service quality (client satisfaction questionnaire;
CSQ-8) at four months.
Results 276 participants were allocated to collaborative care and 305
allocated to usual care. At four months, mean depression score was
11.1 (standard deviation 7.3) for the collaborative care group and 12.7
(6.8) for the usual care group. After adjustment for baseline depression,
mean depression score was 1.33 PHQ-9 points lower (95% confidence
interval 0.35 to 2.31, P=0.009) in participants receiving collaborative
care than in those receiving usual care at four months, and 1.36 points
lower (0.07 to 2.64, P=0.04) at 12 months. Quality of mental health but
not physical health was significantly better for collaborative care than
for usual care at four months, but not 12 months. Anxiety did not differ
between groups. Participants receiving collaborative care were
significantly more satisfied with treatment than those receiving usual
care. The number needed to treat for one patient to drop below the
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accepted diagnostic threshold for depression on the PHQ-9 was 8.4
immediately after treatment, and 6.5 at 12 months.
Conclusions Collaborative care has persistent positive effects up to 12
months after initiation of the intervention and is preferred by patients
over usual care.
Trial registration number ISRCTN32829227.
Introduction
Depression is a long term and relapsing condition, and is set to
become the second largest cause of global disability by 2020.1
The responsibility for treatment in 90-95% of cases rests with
primary care,2 but the organisation of care in this setting is not
optimal for managing depression, with barriers between
generalist and specialist professionals in mental health, poor
patient adherence to pharmacological treatment,3 and limited
specialist support for patients.4 Evidence is developing on the
role of organisational interventions in improving the
management of a range of chronic conditions. Their application
to the management of depression includes “collaborative care,”
a complex intervention developed in the United States
incorporating a multiprofessional approach to patient care; a
structured management plan; scheduled patient follow-ups; and
enhanced interprofessional communication.5 In practice, this
approach is achieved by the introduction of a care manager into
primary care, responsible for delivering care to patients with
depression under the supervision of a specialist, and for liaising
between primary care doctors and mental health specialists.
Systematic reviews have shown that collaborative care improves
depression outcomes, with some studies showing benefit for up
to five years.6 7 Previously, our 2006 systematic review of 28
collaborative care studies showed it to be effective (standardised
mean difference −0.24, 95% confidence interval −0.17 to
−0.32).7
However, most studies have been conducted in the US. In other
areas of mental healthcare, organisational interventions
developed in the US have not generalised outside the original
healthcare context.8 For collaborative care, there is some
supportive evidence from other contexts, including the
developing world,9 10 but uncertainty around the standardised
effect size in trials in the United Kingdom (standardised mean
difference 0.24, 95% confidence interval −0.060 to 0.547) and
elsewhere.7 Owing to these limited non-US data and the
relatively small effect size in trials of patients with depression
alone, the UKNational Institute for Health and Care Excellence
(formerly the National Institute for Health and Clinical
Excellence)11 issued a research recommendation for a fully
powered UK evaluation of collaborative care.
There is considerable variation between study heterogeneity in
terms of the duration and intensity of collaborative care, and in
the training and background of care managers used in the
reported studies. Therefore, we carefully developed our
collaborative care intervention to apply outside the US, in
healthcare systemswith a well developed primary care sector.12-14
In our development work,12 we designed a care management
intervention after systematic review,7 15 in-depth qualitative
interviews with patients, general practitioners, andmental health
workers, and through consultations with the intervention
originators in the US. In our phase II testing of this
intervention,13 we found preliminary evidence indicating that
collaborative care adapted to the UKwas acceptable to patients
and doctors, and could be effective outside the US, but that a
cluster randomised controlled trial was needed to guard against
potential contamination between trial arms.13Consequently, we
undertook a pragmatic cluster randomised trial to determine
whether collaborative care is more clinically effective than usual
care in the management of patients with moderate to severe
depression.
Methods
Study design
The Clinical and Cost Effectiveness of Collaborative Care for
Depression in UK Primary Care Trial (CADET) was a
multicentre, two group, cluster randomised controlled trial.
Setting and participants
We recruited participants between June 2009 and January 2011
from the electronic case records of primary care general practices
in three UK sites: Bristol, London, and greater Manchester.
Eligible participants were adults aged 18 years and older who
met ICD-10 (international classification of diseases, 10th
revision) criteria for a depressive episode when interviewed by
research personnel using the revised Clinical Interview
Schedule.16 We excluded acutely suicidal patients; those with
psychosis, type I or type II bipolar disorder; those whose low
mood was associated with bereavement or whose primary
presenting problem was alcohol or drug abuse; and those
receiving psychological treatment for their depression by
specialist mental health services.
Randomisation, concealment of allocation,
and blinding
We randomly allocated primary care practices as they were
recruited into the trial, minimised within sites by Index of
Multiple Deprivation rank,17 number of general practitioners,
and practice size. The allocation sequence was concealed from
researchers recruiting practices and administered centrally using
Minim.18 The Peninsula Clinical Trials Unit remotely managed
participant identification and data collection. Research workers
blind to allocation, assessed for eligibility and collected outcome
measures using patients’ self report questionnaires to minimise
the effect of potential unblinding. Owing to the nature of the
intervention, it was not possible to blind participants, care
managers, or general practitioners to allocations.
Recruitment
We searched computerised case records from general practices
for patients with at least one identification code in their
electronic records. Several of such codes are widely used by
general practitioners to classify patients as depressed. Practices
contacted identified patients by letter or telephone to seek
permission for researchers to contact them. Research staff
interviewed potential participants that responded, to take consent
and confirm eligibility via the revised Clinical Interview
Schedule.
Intervention and comparator groups
Intervention: collaborative care
Collaborative care, developed in our previous studies, was
delivered by a team of care managers, supervised by mental
health specialists. In addition to usual care from their general
practitioners, care managers were to have six to 12 contacts
with participants over 14 weeks: 30-40 minutes for an initial
appointment face to face, followed by telephone contacts of
15-20 minutes thereafter.
Collaborative care consisted of antidepressant drugmanagement,
behavioural activation,19 symptom assessment, and
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communication between primary care physicians and the care
managers. Care managers advised participants on their drug
adherence and alerted primary care physicians to participant
adherence or tolerance problems so that dose or agent could be
amended. Behavioural activation19 is an effective form of brief
cognitive behavioural therapy, which aims to disrupt depressive
avoidance cycles and increase participants’ activity to provide
more opportunity for exposure to positive mood reinforcing
situations. Care managers assessed symptoms at each contact
using the Hospital Anxiety andDepression Scale20 and discussed
these with participants. Caremanagers also provided participants
with relapse prevention advice.21 Finally, caremanagers provided
general practitioners with regular updates and participant
management advice at least monthly andmore often if clinically
indicated.
We recruited existing mental health workers in primary care
with minimal or paraprofessional education as care managers,
treating CADET participants alongside those patients being
seen as part of their usual NHS role.We provided care managers
with an additional five days’ training in collaborative care and
weekly supervision by specialist professionals in mental health,
including clinical psychologists, psychiatrists, academic general
practitioners with special interest in mental health, or a senior
nurse psychotherapist. Individual participants were discussed
in supervision at least monthly, facilitated through a bespoke
computerised system for patient management (www.pc-mis.co.
uk), which automatically alerted supervisors and care managers
of the need to discuss all participants monthly, and alerted
supervisors to participants not responding to treatment.
Usual care
Participants received care from their general practitioner
according to usual clinical practice for these patients, including
treatment by antidepressants and referral for other treatments.
We recorded every aspect of usual care but did not specify a
treatment programme in line with the pragmatic nature of this
trial.
Outcomes
Our primary outcome was individual participant depression
severity measured by the patient health questionnaire 9
(PHQ-9)22 at four months. Secondary outcomes were the PHQ-9
at 12months; quality of life (short form 36 questionnaire; SF-36)
at baseline, four months, and 12 months23; worry and anxiety
(generalised anxiety disorder; GAD-7)24 at four and 12 months;
and patient satisfaction (client satisfaction questionnaire 8;
CSQ-8)25 at four months.
Sample size
We powered the trial at 90% (α=0.05) to detect an effect size
of 0.4, which we regarded as reasonable for determining
clinically meaningful differences between interventions.26 This
figure was within the 95% confidence intervals of the effect
predicted from data collected during our pilot work (effect size
0.63; 95% confidence interval 0.18 to 1.07).13 However, the
figure was greater than the findings from a meta-analysis of
existing trials available at the time we initiated CADET (0.25;
0.18 to 0.32).7 We would have required 132 participants per
group in a two armed, patient randomised trial. For our cluster
trial, with 12 patients per primary care cluster and an intracluster
correlation of 0.06 from our pilot trial,13 the design effect was
1.65, leading to a sample size of 440. To follow up 440
participants, we aimed to randomise 550 participants
(anticipating 20% attrition). Because recruitment would not be
uniform between practices, we aimed to recruit 48 practices
with up to 14 participants per practice.
Statistical methods
We undertook intention to treat analyses for all outcomes,
reported in accordance with CONSORT guidelines.27 All
analyses were undertaken in Stata 10.1, after a predefined
analysis plan agreed with the trial steering committee. We
analysed available data at four and 12 months by ordinary least
squares or logistic regression. This approach allowed for
clustering by use of robust standard errors, adjusted at the cluster
level for minimisation variables and site; at the individual level
for age; and, where appropriate, the baseline measurement of
the variable. We analysed the effect of missing primary and
secondary outcome data as a sensitivity analysis, estimated by
multiple imputation by chained regression equations28 using all
available scale clinical scores, age, sex, practice variables, site,
and treatment group. To ease interpretation and allow
comparison with published studies, we estimated standard effect
sizes using the baseline standard deviation for all participants
and calculated rates of “recovery” (proportions of participants
with PHQ-9 scores ≤9) and “response” (50% reduction in scores
from baseline).We calculated numbers needed to treat from the
inverse of the absolute risk reduction adjusted for clustering by
practice.
Results
Participant flow and retention
We allocated 53 practices, two of which dropped out after
allocation (fig⇓). These practices were removed from the
minimisation schedule and their data did not influence later
allocations. During recruitment, we found that the cut-off
adopted for the Index of Multiple Deprivation had been set far
too high—with all practices so far recruited being below it. We
changed this cut-off to one close to the median of practices so
far recruited, retaining allocations so far. One practice was found
to have been mistakenly recorded in the wrong geographical
area; it was moved to the correct group, retaining its allocation.
Table 1⇓ shows the final balance achieved. Of the remaining
51 practices, two did not recruit any participants. The mean
number of participants recruited for the remaining 49 practice
clusters was 11.9 (standard deviation 3.9, range 4-20). We
recruited 581 participants in total and followed up 505 (87%)
and 498 (86%) at four and 12 months, respectively.
Baseline characteristics of participants
More than half (56%) of participants fulfilled ICD-10 criteria
for a moderately severe depressive episode, with a further 30%
meeting criteria for severe depression, 14% mild depression,
and 73% having had depression in the past (table 1). Fewer than
half (44%) of participants were in full or part time paid
employment, the mean age was 44.8 years (standard deviation
13.3), and 72%were women. Almost all (98%) participants had
a secondary diagnosis of an anxiety disorder, the most common
being generalised anxiety disorder. Almost two thirds of
participants (64%) reported a longstanding physical illness (for
example, diabetes, asthma, heart disease). At baseline, 83% of
participants had been prescribed antidepressant drugs by their
primary care doctor.
Delivery and receipt of the intervention
Ten care managers provided collaborative care for a mean of
27.6 participants each (standard deviation 16.42, range 4-46).
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Patients received a mean number of 5.6 sessions (4.01, 0-15).
Forty two (15.2%) participants did not attend any sessions with
their care manager, 213 (77.2%) had two or more contacts, and
171 (62.2%) had four or more contacts. The mean total time in
collaborative care was 3.03 hours (standard deviation 2.18) over
a period of 12 weeks (7.75). For those participants who attended
at least one session, the mean duration of sessions was 34.5
minutes (8.2). Most participants in both collaborative care and
usual care groups remained on antidepressant prescriptions
(74.8% v 73.8% at four months; 69.7% v 69.2% at 12 months).
Primary outcome
The mean depression score at four months was 1.33 PHQ-9
points lower (95% confidence interval 0.35 to 2.31, P=0.009)
in participants receiving collaborative care than those receiving
usual care (table 2⇓) after adjustment for baseline depression.
This difference equated to a standardised effect size of 0.26
(0.07 to 0.46). More participants receiving collaborative care
than those receiving usual care met criteria for recovery (odds
ratio 1.67 (95% confidence interval 1.22 to 2.29); number
needed to treat=8.4) and response (1.77 (1.22 to 2.58); 7.8; table
3⇓).
Secondary outcomes
At 12 month follow-up, mean PHQ-9 score was 1.36 points
lower (95% confidence interval 0.07 to 2.64, P=0.04) in
participants receiving collaborative care than in those receiving
usual care (standardised effect size 0.28 (95% confidence
interval 0.01 to 0.52)). More participants in collaborative care
than those in usual care met criteria for recovery (odds ratio
1.88 (95% confidence interval 1.28 to 2.75); number needed to
treat=6.5) and response (1.73 (1.22 to 2.44); 7.3; tables 2 and
3).
Collaborative care produced better outcomes than usual care on
the mental component scale of the SF-36 at four but not 12
months, had little effect on anxiety and the physical component
scale of the SF-36, and participants receiving collaborative care
were more satisfied with their treatment than those in usual care
(table 2).
Missing data
Multiple imputation data using least squares regression and 100
multiple datasets for the primary outcome produced an imputed
estimate that was similar to the available data (PHQ-9 coefficient
−1.31 (95% confidence interval −2.37 to −0.26), P=0.02). We
also found very little difference between the results of our
analyses of available data and imputed data on any secondary
outcomes at four and 12 month follow-up. This similarity
showed that all analyses were not substantively affected by
missing data or differential rates of follow-up between trial
arms.
Discussion
We found that collaborative care improves depression
immediately after treatment compared to usual care, which has
effects that persist to 12 month follow-up and is preferred by
patients over usual care. Our observed effect size (0.26) was
less than that used to power the study, although the 95%
confidence intervals around it (0.07 to 0.46) encompassed our
original target effect size (0.4). Our result was also within the
95% confidence interval of the standardised mean difference
found in the 2012 Cochrane meta-analysis of 79 randomised
controlled trials (overall standardised mean difference 0.29,
95% confidence interval 0.23 to 0.36).6 This analysis included
our results, and was no different from trials in the US (0.28,
0.21 to 0.35), non-US regions excluding the UK (0.36, 0.13 to
0.59), and the UK (0.32, 0.07 to 0.57). Collaborative care is as
effective in the UK healthcare system—an example of an
integrated health system with a well developed primary care
sector—as in the US. Our study adds to the emerging
international literature from countries such as Chile9 and India10
indicating that collaborative care is a model that reliably
generalises outside the US.
Strengths and limitations of the study
To our knowledge, CADET is the one of the largest studies of
collaborative care. Less than 50% of published collaborative
care trials have followed up participants for 12 or more months,
and our levels of attrition at four and 12 months are comparable
with 70% of collaborative care trials and better than other trials
of brief interventions in this area.29 There was no evidence that
missing follow-up data biased findings. Although our cluster
design protected against contamination of the usual care arm
by changes in behaviour being tested in the collaborative care
arm, cluster trials are prone to selection bias. We minimised
this bias by recruiting participants through electronic case note
searches rather than doctor referral.
Owing to the nature of the intervention and comparator, we
could not blind general practitioners, patients, or care managers
to treatment allocation. However, we used self reported outcome
measures to minimise the effect of detection bias. We relied on
self reported records of care manager contacts, and thus have
nomeans to assess record accuracy. Caremanagers were already
employed by organisations providing primary care services for
mental health in the UK’s health service. However, supervisors
were senior members of the investigator group, so it is unclear
how much their—albeit minimal—supervision can be
generalised beyond the trial.
Our intervention was brief, so a more intensive intervention
might have improved outcomes further, particularly for the more
complex cases. We could have chosen a different psychological
intervention such as cognitive behavioural therapy,30 but
reviews19 and controlled trials31 have shown behavioural
activation to be as effective as cognitive behavioural
therapy—potentially more so for severe cases32—and can be
delivered effectively by junior healthcare personnel.31 We are
currently conducting a process evaluation including analysis of
any dose response, to determine the effect on outcomes of
intervention content, process mediators, and participant
characteristics.
Implications for practice and directions for
future research
During the time we undertook CADET, the number of
international trials of collaborative care more than doubled,
albeit many of them still conducted in the US. While the
portability of a US collaborative care model to the UK had been
suggested by previous small scale studies, CADET has provided
definitive confirmation of that portability. The CADET trial
findings answered a specific need highlighted in the NICE
guidelines for depression and provided critical evidence for
further service delivery.
Although our results sit within the expected effect range of
collaborative care reported in the latest meta-analysis of
international collaborative care trials,6 the clinical implications
of our results are more difficult to interpret. The average
difference in treatment response was less than what we had
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expected (effect size 0.26 v 0.4), and these more modest
differences were sustained over the longer term. Between group
differences can obscure response rates in individual patients.
We have, therefore, presented the data on meaningful clinical
differences (table 3) using numbers needed to treat and two
criteria commonly applied in the depression literature and
regarded as clinically meaningful. These criteria were recovery
(falling below a recognised point on the PHQ-9 symptom scale);
and response (a 50% reduction in symptoms of depression).
Using these metrics, it is particularly noteworthy that at 12
months, 56% of participants receiving collaborative care
“recovered”—15% more than in usual care. Health services
would, therefore, need to treat 6.5 patients using collaborative
care to produce one additional patient with a sustained recovery
compared with usual care. Studies achieving higher effects have
been undertaken in countries with less developed services in
primary care than in the UK,9 10 or have used more highly
qualified workers such as nurses or social workers.33 Such
workers are in acute short supply in the UK and hence this model
would not have been translatable for its health system. A full
economic evaluation of CADET is forthcoming, since the
relative magnitude of clinical effects can only be properly
understood in the context of a proper understanding of cost data
relative to effectiveness. The persistence of our treatment effect
at 12 months, however, is noteworthy and unusual in primary
care depression trials.29 We are now conducting a three year
follow-up of our participants to assess further long term effects,
given that only two trials of collaborative care have reported
outcomes beyond 24 months.6
Our results represent a slightly higher recovery rate than that
reported by the UK Improving Access to Psychological
Therapies (IAPT) programme, which has been described in a
Nature editorial as “a world-beating standard.”34Recovery rates
of about 45% have been achieved in IAPT, after an investment
of £700m (€812m; $1085m) over six years.35 We suggest that
integration of our CADET protocol into IAPT services might
enhance outcomes for patients receiving treatment for depression
and provide guidance to international mental health services
that this model can be applicable outside the US.
Although collaborative care is an organisational intervention
that improves outcomes, much remains to be done to improve
the effectiveness of treatments for depression. Even intensive
psychological treatments for depression have been shown to
achieve only modest gains (effect size of 0.42 in 51 studies).36
Our careful selection of intervention ingredients, directed by
our identification of components present in the better performing
trials from our previous meta-regression,15 did not succeed in
achieving the larger effects we had hoped for. In CADET, 44%
of participants receiving collaborative care had scores that
remained above the PHQ-9 depression threshold at 12 month
follow-up. Future trials should test enhancements of the basic
collaborative care model by developing, testing, and delivering
better treatments within the effective collaborative care
organisational framework, rather than test collaborative care
itself, given that the effects of collaborative care are now firmly
established.
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What is already known on this topic
Although systematic reviews have shown that collaborative care improves depression outcomes, most studies have been conducted in
the US
In other areas of mental healthcare, the positive effects of organisational interventions developed in the US have not generalised outside
the original healthcare context
Despite some preliminary evidence in non-US regions, there is uncertainty in meta-analyses around the true effect of collaborative care
outside the US
What this study adds
Collaborative care improves depression immediately after treatment compared with usual care, which has effects persisting up to 12
month follow-up and is preferred by patients over usual care
The portability of a model of collaborative care in the US had been suggested by small scale studies; the CADET trial has provided a
definitive confirmation of that portability
Although collaborative care is an organisational intervention that improves outcomes, better treatments are still needed to increase
recovery rates in depression above the current 50-55%
25 Attkisson C, Zwick R. The client satisfaction questionnaire: psychometric properties and
correlations with service utilisation and psychotherapy outcome. Eval Program Plann
2003;5:233-37.
26 Elliott R, Stiles WB, Shapiro DA. Are some psychotherapies more equivalent than others?
In: Giles TR, ed. Handbook of Effective Psychotherapy. Plenum Press, 1993:455-79.
27 Campbell MK, Elbourne DR, Altman DG. CONSORT statement:extension to cluster
randomised trials. BMJ 2004;328:702-8.
28 Royston P. Multiple imputation of missing values. Stata J 2004;4:227-41.
29 Cape J, Whittington C, Buszewicz M, Wallace P, Underwood L. Brief psychological
therapies for anxiety and depression in primary care: meta-analysis and meta-regression.
BMC Med 2010;8.
30 Beck AT, Rush A, Shaw B, Emery G. Cognitive therapy of depression: a treatment manual.
Guilford Press, 1979.
31 Ekers D, Richards D, McMillan D, Bland JM, Gilbody S. Behavioural activation delivered
by the non-specialist: phase II randomised controlled trial. Br J Psychiatry 2011;198:66-72.
32 Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al.
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication
in the acute treatment of adults with major depression. J Consult Clin Psychol
2006;74:658-70.
33 Unutzer J, KatonW, Callahan CM,Williams JW, Hunkeler E, Harpole L, et al. Collaborative
care management of late-life depression in the primary care setting: a randomized
controlled trial. JAMA 2002;288:2836-45.
34 Nature. Therapy deficit: studies to enhance psychological treatments are scandalously
under-supported [editorial]. Nature 2012;486:473-4.
35 Department of Health. IAPT three-year report. The first million patients. Department of
Health, 2012.
36 Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, AnderssonG. Efficacy of cognitive-behavioural
therapy and other psychological treatments for adult depression: meta-analytic study of
publication bias. Br J Psychiatry 2010;196:173-8.
Accepted: 26 July 2013
Cite this as: BMJ 2013;347:f4913
This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/3.0/.
Open Access: Reuse allowed Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4913 doi: 10.1136/bmj.f4913 (Published 19 August 2013) Page 6 of 10
RESEARCH
Tables
Table 1| Baseline characteristics of participants
Total (n=581)Usual care (n=305)Collaborative care (n=276)
No of general practices by centre
1798Bristol
1899London
1697Manchester
Minimisation variables
8807 (6651)8449 (6012)9210 (7416)Mean Index of Multiple Deprivation (SD)
3.9 (1.9)4.0 (1.9)3.8 (2.0)Mean no of general practitioners (SD)
6899 (3530)7152 (3781)6615 (3282)Mean no of patients (SD)
Sex
418 (71.9)216 (70.8)202 (73.2)Female
163 (28.1)89 (29.2)74 (26.8)Male
Age (years)
44.8 (13.3)44.5 (13.4)45.0 (13.2)Mean (SD)
17-8217-7918-82Range
Ethnic origin
494 (85.0)261 (85.6)233 (84.4)White British
87 (15.0)44 (14.4)43 (15.6)Other
Education
128 (22.0)74 (24.3)54 (19.6)None
146 (25.1)81 (26.6)65 (23.6)GCSE or O level
163 (28.1)79 (25.9)84 (30.4)Post-GCSE or O level
102 (17.6)53 (17.4)49 (17.8)Degree or higher
42 (7.2)18 (5.9)24 (8.7)Other or don’t know
Employment
252 (43.5)*122 (40.0)130 (47.4)*Employed or self employed
327 (56.5)183 (60.0)144 (52.6)Not working
Marital status
241 (41.5)114 (37.4)127 (46.0)Married or cohabiting
Antidepressant treatment
480 (82.6)249 (81.6)231 (83.7)Prescribed antidepressants
Revised Clinical Interview Schedule score
29.6 (9.1)30.3 (8.9)28.8 (9.3)Mean (SD)
ICD-10 diagnosis†
83 (14.3)41 (13.4)42 (15.2)Mild
323 (55.6)167 (54.8)156 (56.5)Moderate
174 (29.9)96 (31.5)78 (28.3)Severe
History of depression
422 (72.6)220 (72.1)202 (73.2)Previous episode
Secondary diagnosis
570 (98.1)301 (98.7)269 (97.5)Any anxiety disorder
370 (63.7)199 (65.2)171 (62.0)Longstanding physical illness
Data are number (%) of participants unless stated otherwise. SD=standard deviation.
*Employment data were missing for two participants.
†One participant did not meet ICD-10 criteria for mild, moderate, or severe depression on the revised Clinical Interview Schedule score.
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Table 2| Intention to treat analysis of primary and secondary outcomes at four and 12 month follow-up
Effect sizeP
Adjusted difference
(95% CI)
Usual careCollaborative care
Mean (SD)
No of
participantsMean (SD)
No of
participants
Primary outcome
———18.1 (5.0)30517.4 (5.2)276PHQ-9, baseline
0.260.009−1.33 (−2.31 to −0.35)12.7 (6.8)27511.1 (7.3)230PHQ-9, 4 months*
Secondary outcomes
0.280.04−1.36 (−2.64 to −0.07)11.7 (6.8)26310.0 (7.1)235PHQ-9, 12 months*
———13.6 (4.7)30512.9 (5.3)276GAD-7, baseline
0.080.4−0.39 (−1.30 to 0.53)9.8 (5.8)2739.1 (6.8)228GAD-7, 4 months
0.220.06−1.09 (−2.21 to 0.03)9.1 (6.2)2537.7 (6.2)227GAD-7, 12 months
———22.3 (10.3)30523.2 (10.4)276SF-36 MCS, baseline
0.330.0053.4 (1.1 to 5.7)30.7 (13.7)26834.6 (15.4)227SF-36 MCS, 4 months
0.240.12.5 (−0.6 to 5.5)33.4 (14.5)24936.4 (15.0)223SF-36 MCS, 12 months
———44.5 (12.3)30544.8 (12.4)276SF-36 PCS, baseline
-0.0040.90.05 (−1.67 to 1.56)45.6 (13.8)26845.8 (13.2)227SF-36 PCS, 4 months
0.080.31.04 (−0.93 to 3.01)44.9 (13.3)24946.1 (13.2)223SF-36 PCS, 12 months
0.52<0.0013.13 (1.87 to 4.39)22.1 (6.2)26925.3 (5.8)232CSQ-8, 4 months
SD=standard deviation; MCS=mental component; PCS=physical component.
*One participant committed suicide. Because the PHQ-9 data for this person could not be regarded as missing at random, PHQ-9 data at four and 12 months were
set to the maximum 27 and included in analysis.
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Table 3| Recovery, response, and numbers needed to treat*
No needed
to treat§P‡
Odds ratio† (95%
CI‡)
Usual careCollaborative care
No (%) of recovered
or responded
participants
No of
participants
No (%) of recovered
or responded
participants
No of
participants
Recovery (PHQ-9 score ≤9 at follow-up)
8.40.0011.67 (1.22 to 2.29)96 (34.9)275108 (47.0)2304 months
6.50.0011.88 (1.28 to 2.75)106 (40.3)263131 (55.7)23512 months
Response (≥50% reduction in PHQ-9 score at follow-up v PHQ-9 score at baseline)
7.80.0031.77 (1.22 to 2.58)83 (30.2)27599 (43.0)2304 months
7.30.0021.73 (1.22 to 2.44)93 (35.4)263115 (48.9)23512 months
*One participant committed suicide. Because the PHQ-9 data for this person could not be regarded as missing at random, PHQ-9 data at four and 12 months were
set to the maximum 27 and included in analysis.
†Adjusted for age, site, and minimisation variables.
‡Adjusted for clustering by practice.
§For numbers needed to treat, inverse of absolute risk reduction adjusted for clustering by practice.
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Figure
CONSORT diagram. *The five patients in the collaborative care group who were excluded on interview because they were
receiving treatment from secondary care or another mental health provider (n=5) included one participant who was initially
allocated in error and subsequently excluded
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